Kivu Bioscience Presents Preclinical Data for KIVU-107 Demonstrating Potent and Durable Anti-Tumor Activity and a Wide Therapeutic Index at World ADC San Diego 2025

KIVU-107 is the first PTK7-targeting ADC with a DAR4 exatecan payload, engineered for exceptional stability and highly selective on-tumor delivery. Preclinical data demonstrate deeper and durable anti-tumor activity across multiple xenograft models, with a wide therapeutic index and well-tolerated profile in repeat-dose GLP studies. Kivu to initiate a Phase 1 clinical study of KIVU-107 this quarter. SAN MATEO, Calif.–( BUSINESS WIRE )– Kivu Bioscience , a biotechnology company advancing next-generation antibody-drug conjugates (ADCs) for difficult-to-treat cancers, today announced that it will present new preclinical activity and safety data for KIVU-107, a best-in-class PTK7-targeting ADC, at the 16 th World ADC San Diego, held November 3-6, 2025. The data will be featured in both an oral and poster presentation highlighting the unique biophysical and therapeutic properties of KIVU-107, and its potential to set a new standard among next-generation ADCs. KIVU-107 is a PTK7-targeting ADC generated via site-specific GlycoConnect™ and HydraSpace™ conjugation technologies. It is designed to be highly stable in circulation, with negligible free payload release, maximizing on-tumor activity while minimizing off-target toxicity. The ADC leverages an exatecan payload (SYNtecan E™) with an optimized drug-antibody ratio (DAR), resulting in a wider therapeutic index and deeper, more durable responses in preclinical tumor models. “These preclinical data highlight the potential of KIVU-107 as a next-generation ADC designed to deliver enhanced efficacy, superior stability, and improved tolerability,” said Mohit Trikha, Ph.D., President and Chief Operating Officer, Kivu Bioscience. “In preclinical studies, KIVU-107 is both highly potent and exceptionally well-tolerated, a combination that’s rare among ADCs. We look forward to initiating our Phase 1 clinical trial this quarter.” Both the oral and poster presentations feature preclinical data highlighting KIVU-107’s strong anti-tumor activity, and excellent safety profile. KIVU-107 demonstrated potent antigen-specific cytotoxicity with rapid internalization in vitro and. in mouse xenograft models, durable complete tumor regressions were observed after a single dose. KIVU-107 also showed robust activity in combination with olaparib and in ADC-resistant patient-derived xenograft models, supporting its potential to overcome resistance mechanisms seen with current ADC therapies. Repeat-dose GLP toxicology studies in non-human primates demonstrated favorable pharmacokinetics, minimal unconjugated exatecan exposure, and an exceptional tolerability profile supporting a potential higher starting dose for first-in-human evaluation. Together, these findings confirm a wide therapeutic index and a best-in-class potential for efficacy, stability, and safety. The preclinical data collectively demonstrate that KIVU-107 combines precision targeting with a potent and controllable payload, resulting in a differentiated ADC profile with a remarkably wide therapeutic index. Presentation Details: Oral Presentation Title: Striving for Kinder and Gentler ADCs: Spotlight on Solid Tumor Target and Preclinical Development of KIVU-107 Presenter: Mohit Trikha, Ph.D. Session: Discovery Biology Date/Time: Tuesday, November 4, 3:00 PM PT Poster Presentation Title: Preclinical Efficacy and Safety of KIVU-107, a Novel PTK7-Targeting Antibody-Drug Conjugate (ADC) Authors: N. Viller, L. Zhang, X. Jiang, A. MacLaren, M. Trikha Session: Day 2 Poster Session Poster Number: 84 Date/Time: Wednesday, November 5, 8 AM – 6 PM PT About Kivu Bioscience Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company’s proprietary linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing its lead candidates to clinical trials. The company is headquartered in San Mateo, CA. For more information, visit www.kivubioscience.com . Contacts Media Kimberly Ha KKH Advisors 917-291-5744 [email protected] Prev Previous Kivu Bioscience Selects Sterling Pharma Solutions for cGMP Manufacturing of Lead Oncology Antibody-Drug Conjugate KIVU-107 Next Kivu Bioscience Appoints Sophia Randolph, M.D., Chief Medical Officer Next 2929 Campus Drive, Suite 420, San Mateo CA 94403 Linkedin Site by BKW © 2026 Kivu Bioscience Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage Consent To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions. Functional Functional Always active The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network. Preferences Preferences The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user. Statistics Statistics The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you. Marketing Marketing The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes. Manage options Manage services Manage {vendor_count} vendors Read more about these purposes Accept Deny View preferences Save preferences View preferences {title} {title} {title} Manage consent Manage consent

The release as fetched from its publisher. kivubioscience.com ↗